Production (Stage)
Kiora Pharmaceuticals, Inc.
KPRX
$3.08
-$0.01-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 175.85% | -353.42% | |||
| Gross Profit | -175.85% | 353.42% | |||
| SG&A Expenses | 12.25% | -3.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.00% | -7.12% | |||
| Operating Income | 18.00% | 7.12% | |||
| Income Before Tax | 4.10% | 36.76% | |||
| Income Tax Expenses | -94.04% | -- | |||
| Earnings from Continuing Operations | 48.08% | -23.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.08% | -23.74% | |||
| EBIT | 18.00% | 7.12% | |||
| EBITDA | 17.82% | 7.26% | |||
| EPS Basic | 48.07% | -23.65% | |||
| Normalized Basic EPS | 9.86% | 20.69% | |||
| EPS Diluted | 48.08% | -23.65% | |||
| Normalized Diluted EPS | 9.86% | 20.69% | |||
| Average Basic Shares Outstanding | -0.03% | 0.08% | |||
| Average Diluted Shares Outstanding | -0.03% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||